Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
L-Tryptophan

when sold, a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other indredients; or b) for human or veterinary use as a single ingredient inteded for any route of administration other than oral

I DEC / 13
Labetalol or its salts I DEC / 13
Lacosamide or its derivatives I DEC / 13
Lactic acid

When recommended for parenteral use as a tissue sclerosing agent.

I DEC / 13
Lactulose III SEP / 98
Lamivudine or its salts I DEC / 13
Lamotrigine or its salts I DEC / 13
Lanadelumab I NOV / 18
Lanreotide or its salts I DEC / 13
Lansoprazole or its salts I DEC / 13
Lanthanum salts

For human use - when sold for the treatment of hyperphosphatemia.

I DEC / 13
Lapatinib or its salts I DEC / 13
Laronidase I DEC / 13
Larotrectinib or its salts I OCT / 19
Ledipasvir or its salts I DEC / 14
Lefamulin or its salts I SEP / 20
Lefetamine, its salts, derivatives and isomers and salts of derivatives and isomersC I JAN / 03
Leflunomide or its salts or derivatives

Including but not limited to teriflunomide. 

I DEC / 13
Lemborexant or its saltsPDL I DEC / 20
Lenalidomide I DEC / 13
Lenvatinib or its salts I AUG / 16
Letermovir or its salts I DEC / 17
Letrozole I DEC / 13
Leucovorin or its salts I DEC / 13
Leuprolide or its salts I DEC / 13
Levallorphane and its salts I SEP / 98
Levamisole or its salts

For human use. 

I DEC / 13
Levargorphane and its salts II SEP / 98
Levetiracetam I DEC / 13
Levobunolol or its salts I DEC / 13
Levocabastine or its salts or derivatives I DEC / 13
Levocarnitine or its salts or derivatives

When sold for the treatment of primary or secondary levocarnitine deficiency.

I DEC / 13
Levodopa or its salts I DEC / 13
Levomilnacipran or its salts I JUN / 15
Levonordefrine II SEP / 98
Levonorgestrel when sold in concentrations of 1.5 mg or less per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.) II MAY / 15
Levonorgestrel. when sold in concentrations of 1.5 mg or less per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel III MAY / 15
Lidocaine

For human use - when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher.

I FEB / 14
Lidocaine and its salts for ophthalmic or parenteral use, or topical use on mucous membranes, except lozenges II SEP / 98
Lidocaine and its salts.

for otic use

III JUN / 06
Lidocaine and its salts..

for topical use on the skin, including lozenges [except when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher]

U FEB / 14
Lidocaine and prilocaine eutectic mixture III FEB / 99
Lifitegrast or its salts I MAR / 18
Linaclotide or its salts or derivatives I DEC / 13
Linagliptin or its salts or derivatives I DEC / 13
Lincomycin or its salts or derivatives

Including but not limited to: Clindamycin 

I DEC / 18
Lindane II SEP / 98
Linezolid or its salts I DEC / 13
Liothyronine or its salts

For human use. 

I DEC / 13
Lipid solutions in injectable form for parenteral nutrition I JAN / 03
Liraglutide or its salts I DEC / 13
Lisinopril or its salts or derivatives I DEC / 13
Lithium or its salts I DEC / 13
Lixisenatide or its salts I JUN / 17
Lodoxamide or its salts or derivatives

Including but not limited to Lodoxamide tromethamine.

I DEC / 13
Lomefloxacin or its salts I DEC / 13
Lomitapide or its salts I FEB / 14
Lomustine I DEC / 13
Loperamide and its salts in products marketed for adult use (12 years and older) U APR / 07
Loperamide and its salts. in products marketed for paediatric use (under 12 years of age) II APR / 07
Lopinavir I DEC / 13
Loratadine and its salts and preparations in products marketed for paediatric use - under 12 years of age III OCT / 02
Loratadine and its salts and preparations. in products marketed for adult use - 12 years and older U OCT / 02
Lorlatinib or its salts I MAR / 19
Losartan or its salts I DEC / 13
Losoxantrone or its salts I DEC / 13
Lotilaner

For veterinary use.

I MAR / 18
Lovastatin

Except in oral dosage form that provides 1 milligram (mg) or less per daily dose.

I DEC / 14
Loxapine or its salts I DEC / 13
Lumacaftor or its salts or derivatives I AUG / 16
Lumiracoxib I DEC / 13
Lurasidone or its salts I DEC / 13
LuspaterceptPDL I DEC / 20
Lutropin alfa I DEC / 13
Lyme Disease vaccine I FEB / 02

75 result(s)


Footnotes

  • C - Drug is listed in the Schedule to Part G of the Food and Drug Regulations under the Controlled Drugs and Substances Act
    N - Drug is listed in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
    NR - Drug has not been reviewed by the NDSAC
    PDL - Drug is listed in the Health Canada Prescription Drug List
    TS - Drug is listed in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
    CR - Drug has been recommended for addition to the Controlled Drugs and Substances Act